Skip to main content
. 2021 Sep 17;14:121. doi: 10.1186/s13048-021-00877-y

Fig. 7.

Fig. 7

UBE2S confers to Olaparib resistance through Wnt/β-catenin in ovarian cancer cells. A The CCK8 assay was performed to determine the cell viability in ovarian cancer cells treated with Olaparib (A2780, 15 μM; SKOV3, 30 μM) or XAV-939 (10 μM) for 48 h. B Clonogenic assay was performed to determine the colony formation efficiency of A2780 and SKOV3 cells treated with Olaparib and XAV-939. C Quantification of the number of clones in (B). D The protein of PARP, cleaved caspase 3, and β-actin were detected by western blot in ovarian cancer cells treated with Olaparib (A2780, 15 μM; SKOV3, 30 μM) or XAV-939 (10 μM) for 48 h. E Quantification of the protein levels of cleaved PARP and cleaved caspase 3 in (D). (Data are mean ± SEM, #p > 0.05, *p < 0.05, **p < 0.01, n = 3)